Psychiatry · Autism Spectrum DisorderTrial Updateclinicalmid-term

Feasibility Study of UP-A-AST for Adolescents with Autism and Anxiety/Depression

This study addresses a critical gap in evidence-based interventions for adolescents with Autism Spectrum Disorder (ASD) who also experience anxiety and depression. The outcomes could redefine treatment standards and open new avenues for therapeutic options in this niche market.

Importance7/ 10

ActionMonitor

AutoResearch

Multi-agent research across ingested FDA, EMA, MHRA, PMDA, PubMed, ClinicalTrials.gov, company documents, and Humanexa signals.

Last run 8/4/2026, 12:31:12 AM

Assessment confidence: 82% · The main uncertainty is timing and magnitude of competitive and regulatory follow-through.

Executive Thesis

Strategic Assessment

Success in this trial could lead to new therapeutic options for managing anxiety and depression in adolescents with ASD, impacting market dynamics. The strongest clinical anchor is Study to evaLuate the effIcacy and Safety of abeLacimab in High-risk Patients With Atrial Fibrillation Who Have Been Deemed Unsuitable for Oral antiCoagulation (LILAC-TIMI 76) (ClinicalTrials.gov), sponsor/company relevance (novartis). In Psychiatry · Autism Spectrum Disorder, 0 regulatory and 3 competitive items passed relevance filtering for Unified Protocol-Adolescent Autism Parent Group.

Competitive Pressure

The most relevant competitive pressure comes from Roche's ENSPRYNG shows 68% relapse reduction in Phase III MOGAD study (Humanexa Signals) — sponsor/company relevance (roche). Secondary pressure from Mobile App-Delivered ACT Shows Efficacy in PTSD Treatment in China. This trial addresses a gap in evidence-based interventions for adolescents with ASD, potentially influencing treatment standards in this niche.

Regulatory Outlook

Regulatory risk is concentrated around If the intervention proves effective, it may influence future regulatory approvals for similar therapies targeting co-occurring disorders in this population..

Key Risks

Elevated medium regulatory exposure for Unified Protocol-Adolescent Autism Parent Group could delay market entry or constrain labeling if agency review intensifies.
Evidence gap: no medium- or high-relevance regulatory precedents in ingested corpus.

Key Opportunities

Successful outcomes may lead to new treatment protocols that could enhance market share for companies developing psychiatric interventions tailored for adolescents with ASD.
Upside for Unified Protocol-Adolescent Autism Parent Group may improve if Client and therapist experiences with the Processing of Positive Memories Technique (PPMT) in a randomized controlled trial: insights for protocol refinement. (PubMed) delivers favorable follow-through.
Success in this trial could lead to new therapeutic options for managing anxiety and depression in adolescents with ASD, impacting market dynamics.

What Would Change This Assessment

This becomes more urgent if Monitor outcomes related to psychiatric symptoms and functional impairment, as well as parent feedback on the intervention.
Timeline shift beyond mid term would change urgency.
A competitor label expansion or pivotal readout in the same sub-indication would increase competitive pressure.

Supporting Evidence

No evidence in this category.

Study to evaLuate the effIcacy and Safety of abeLacimab in High-risk Patients With Atrial Fibrillation Who Have Been Deemed Unsuitable for Oral antiCoagulation (LILAC-TIMI 76)
ClinicalTrials.govhigh relevance
Sponsor/company relevance (Novartis)
FDA document
View source
Efficacy of Gamified Blended Mindfulness Program to Reduce Burnout, Stress, and Anxiety in Nursing Students: A Randomized Controlled Trial
ClinicalTrials.govhigh relevance
Moderate corpus alignment
FDA document
View source
Operation Calm: VR Nature-Based Mindfulness to Reduce Pediatric Surgical Anxiety
ClinicalTrials.govhigh relevance
Moderate corpus alignment
FDA document
View source
Effect of Family Participation-Based Intervention Before Coronary Artery Bypass Grafting (CABG) on Patients' Anxiety, Independence, and Psychological Resilience: A Randomized Controlled Trial
ClinicalTrials.govhigh relevance
Moderate corpus alignment
FDA document
View source
Effects of Nurse-Led Self-Compassion and Kindness Program on Compassion and Healthy Peer Relationships Among Adolescents: A Randomized Controlled Trial
ClinicalTrials.govhigh relevance
Moderate corpus alignment
FDA document
View source
A Study of Varipulse Catheter in Participants With Paroxysmal Atrial Fibrillation Under Optimized Sedation
ClinicalTrials.govhigh relevance
Moderate corpus alignment
FDA document
View source
Feasibility and Acceptability of Collecting Sociodemographic Data in CCTG Trials
ClinicalTrials.govhigh relevance
Moderate corpus alignment
FDA document
View source
Daridorexant for People With Insomnia and Alcohol Use Disorder Study
ClinicalTrials.govhigh relevance
Moderate corpus alignment
FDA document
View source

Roche's ENSPRYNG shows 68% relapse reduction in Phase III MOGAD study
Humanexa Signalshigh relevance
Sponsor/company relevance (Roche)
Mobile App-Delivered ACT Shows Efficacy in PTSD Treatment in China
Humanexa Signalsmedium relevance
Moderate corpus alignment
Study on Multivirus CTL for Viral Infections Post Allogeneic SCT Shows Promise
Humanexa Signalsmedium relevance
Moderate corpus alignment

Do subjective and objective baseline sleep disturbances predict post-traumatic stress disorder treatment response? A secondary analysis of a randomized controlled trial.
PubMedhigh relevance
Moderate corpus alignment
FDA document
View source
High-flow nasal cannula oxygenation in sedated endoscopy for high-risk obstructive sleep apnea patients: study protocol for a multicentre randomised controlled trial.
PubMedhigh relevance
Moderate corpus alignment
FDA document
View source
Client and therapist experiences with the Processing of Positive Memories Technique (PPMT) in a randomized controlled trial: insights for protocol refinement.
PubMedhigh relevance
Moderate corpus alignment
FDA document
View source
Mechanisms of change in mobile app-delivered acceptance and commitment therapy for posttraumatic stress disorder in China: a secondary analysis of a randomized controlled trial.
PubMedhigh relevance
Moderate corpus alignment
FDA document
View source
Integrated exposure-based therapy for co-occurring post-traumatic stress and substance use among young people: a randomized controlled trial.
PubMedhigh relevance
Moderate corpus alignment
FDA document
View source
A phase 3, randomized study to evaluate the safety, tolerability, and immunogenicity of V116 in children and adolescents with increased risk of pneumococcal disease (STRIDE-13).
PubMedhigh relevance
Moderate corpus alignment
FDA document
View source
Amino acid infusion and acute kidney injury after aortic surgery: a multicenter observational study with target trial emulation.
PubMedhigh relevance
Moderate corpus alignment
FDA document
View source

Regunera

Precedents · guidance

Reg

Loading regulatory precedents…

View full regulatory analysis

Competitiva

Competitors · threats

Intel

Loading competitive findings…

View full competitive analysis

Why this matters

Affected entities

Unified Protocol-Adolescent Autism Parent Group
adolescents with Autism Spectrum Disorder
pharmaceutical companies focusing on psychiatric treatments

Commercial impact

medium

Successful outcomes may lead to new treatment protocols that could enhance market share for companies developing psychiatric interventions tailored for adolescents with ASD.

Regulatory impact

medium

If the intervention proves effective, it may influence future regulatory approvals for similar therapies targeting co-occurring disorders in this population.

What to watch

Monitor outcomes related to psychiatric symptoms and functional impairment, as well as parent feedback on the intervention.

Recommended action

Monitor

Track for follow-up milestones; no immediate action required.